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The chronic inﬂammatory state in sickle cell anemia (SCA) is associated with several factors such as the
following: endothelial damage; increased production of reactive oxygen species; hemolysis; increased
expression of adhesion molecules by leukocytes, erythrocytes, and platelets; and increased production
of proinﬂammatory cytokines. Genetic characteristics affecting the clinical severity of SCA include vari-
ations in the hemoglobin F (HbF) level, coexistence of alpha-thalassemia, and the haplotype associated
with the HbS gene. The different haplotypes of SCA are Bantu, Benin, Senegal, Cameroon, and Arab-Indian.
These haplotypes are associated with ethnic groups and also based on the geographical origin. Studies
have shown that the Bantu haplotype is associated with higher incidence of clinical complications than
the other haplotypes and is therefore considered to have the worst prognosis. This study aimed to eval-
uate the proﬁle of the proinﬂammatory cytokines interleukin-6, tumor necrosis factor-a, and interleukin-
17 in patients with SCA and also to assess the haplotypes associated with beta globin cluster S (HBBS).
We analyzed a total of 62 patients who had SCA and had been treated with hydroxyurea; they had
received a dose ranging between 15 and 25 (20.0 ± 0.6) mg/kg/day for 6–60 (18 ± 3.4) months; their data
were compared with those for 30 normal individuals. The presence of HbS was detected and the haplo-
types of the beta S gene cluster were analyzed by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP). Our study demonstrated that SCA patients have increased inﬂammatory pro-
ﬁle when compared to the healthy individuals. Further, analysis of the association between the haplo-
types and inﬂammatory proﬁle showed that the levels of IL-6 and TNF-a were greater in subjects with
the Bantu/Bantu haplotype than in subjects with the Benin/Benin haplotype. The Bantu/Benin haplotype
individuals had lower levels of cytokines than those with the Bantu/Bantu haplotype and greater levels
than those of subjects with the Benin/Benin haplotype. For IL-17, a slight trend toward decreased levels
was observed in the subjects with the Benin/Benin haplotype, when compared to those with the Bantu/
Bantu and Bantu/Benin haplotypes; however, this difference was not statistically signiﬁcant. Our results
show that genetic polymorphisms in sickle cell anemia are associated with the inﬂammatory proﬁle.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Sickle cell anemia (SCA) is a hereditary disorder characterized
by severe hemolytic anemia with different clinical manifestations
and is considered as a chronic inﬂammatory disease. SCA results
from a mutation in the sixth codon of the beta globin gene, which
results in the substitution of glutamic acid for valine and leads to
the production of an altered form of hemoglobin, hemoglobin S(HbS) [1]. Patients with SCA exhibit a chronic inﬂammatory state-
and reduced length and quality of life [2].
The basic pathophysiological mechanism is based upon the
polymerization of HbS and the ensuing deformation, rigidiﬁcation,
and fragilization leading to the main hallmarks of the disease, that
is, hemolytic anemia and vaso-occlusive events [3]. Vaso-occlusion
is the result of adhesive interactions between the sickle erythro-
cytes, leukocytes, platelets, plasma and the vessel wall. Recurrent
vaso-occlusions, hemolytic events. and endothelial cell activation
induce a continuous inﬂammatory response in SCA, which mani-
fests as increased levels of inﬂammatory cytokines, decreased bio-
availability of nitric oxide, and oxidative stress[4,5]. Inﬂammatory
cytokines such as TNF-a, IL-6, and IL-17 have been shown to be
218 I.C.J. Bandeira et al. / Cytokine 65 (2014) 217–221important in the inﬂammatory process, since they are produced by
activated endothelial cells and in turn play a signiﬁcant role in
vaso-occlusive crisis in sickle cell disease [6–12].
Studies have indicated that TNF-a is the main mediator of
the acute inﬂammatory response recruiting neutrophils and
monocytes to the site of inﬂammation. Elevated plasma levels of
TNF-a stimulate the production of IL-6, which in turn is also
responsible for the release of acute phase proteins in inﬂammation.
IL-17 is directly involved in the inﬂammatory process; it activates
endothelial cells and stimulates macrophages to produce more
inﬂammatory cytokines such as IL-6 and TNF-a [12–14]. It then
mounts a chronic inﬂammatory state that ensues even during the
steady state condition. Studies have shown high levels of cytokines
in SCA patients even during the steady state [9,15,16].
Although all SCA patients have the same genetic variation, they
show wide variability in the frequency and clinical severity of
vaso-occlusive crises. Therefore, additional factors must contribute
to the pathophysiology of vaso-occlusion [17,18].
Genetic factors acting as clinical modulators include the haplo-
types associated with the HbS gene, variations in the HbF level, and
coexistence of alpha-thalassemia. The haplotypes of SCA can inﬂu-
ence the concentration of HbF and modify the clinical severity of
SCA through the presence of SNPs (single nucleotide polymor-
phisms) that have regulatory inﬂuence on c-globin genes [19,20].
The different haplotypes of SCA are classiﬁed according to the eth-
nic groups and geographic region from where they were ﬁrst iden-
tiﬁed and are as follows: Bantu, Benin, Senegal, Cameroon, and
Arab-Indian. In Brazil, the Bantu and Benin haplotypes are mainly
found [19,21–23].
Data obtained from earlier studies suggest that haplotype anal-
ysis of SCA can serve as a useful marker of the gravity and for
determining phenotypic heterogeneity [24,25]. Studies have
shown that the Bantu haplotype is associated with the more severe
forms of SCA than the Benin haplotype [21,23,26–29].
The aims of the present study were to measure the plasma con-
centrations of IL-6, IL-17, and TNF-a in SCA patients and healthy
subjects as well as to assess the Inﬂuence of HBBS gene haplotypes
on the inﬂammatory proﬁle of patients with SCA. A study never
conducted previously.2. Materials and methods
2.1. Subjects and samples
This is a cross-sectional study of 62 patients (men, 46) who
were diagnosed with sickle cell anemia on the basis of clinical data
as well laboratory test results (homozygotic SS form). The patients
were aged 21–66 (34.9 ± 2.3) years and were receiving oral
hydroxyurea; the dose was between 15 and 25 (20.0 ± 0.6) mg/
kg/d and was administered for 6–60 (18 ± 3.4) months. These pa-
tients represented 50% of the patient population attending the out-
patient unit of the hematology service of a reference hospital in
Fortaleza, CE, Brazil. We measured the levels of various cytokines
and analyzed the HBBS gene haplotypes using the blood samples
from the SCA patients (SS hemoglobinopathy) and the control
group, which was composed of 30 healthy individuals (men, 19)
aged 22–53 (31 ± 2.1) years.
All SCA patients, were evaluated in the ‘‘steady state’’ [30]. Gi-
ven the severity of SCA, all individuals evaluated at our hematolog-
ical services receive treatment; therefore, comparison with
untreated controls is not possible and healthy individuals were
used as controls.
Peripheral blood (10 mL) was collected into EDTA tubes for DNA
isolation and cytokine analysis.All the participants signed an in-
formed consent form, and the study was carried out according tothe Research Ethics Committee of the University Hospital Walter
Cantidio University Hospital, Federal University of Ceara (HUWC/
UFC). The study protocol was reviewed and approved by the Local
Research Ethics Committee.2.2. Molecular biological analysis
DNA was isolated from leukocytes following the protocol of
Sambrook et al. [31]. The presence of HbS was conﬁrmed by poly-
merase chain reaction–restriction fragment length polymorphism
(PCR–RFLP), according to the methods of Saiki et al. [32]. The hap-
lotypes of the beta S gene cluster were analyzed by PCR–RFLP, with
analysis of six polymorphic restriction sites performed according
to the methods of Sutton et al., [33]: 50cGXmn I, cGHind III, cA-
Hind III, wb-Hind II, 30wb-Hind II, and 50b-Hinf I. The bS haplotype
was constructed according to the absence () or presence (+) of
each of the 6 restriction enzyme sites. Table 1 shows the restriction
enzymes used for each region of the DNA, the fragment size after
DNA ampliﬁcation and after digestion with the enzyme, and the
polymorphism pattern for each haplotype.2.3. Measurement of cytokines
Blood samples were taken in the morning, between 7 am and
8 am after an overnight fast. Blood was processed within 1 h of col-
lection, and plasma was aliquoted and stored at 80 C until anal-
ysis. Levels of cytokines in the plasma were measured using
commercially available human ELISA kits (IL-6, catalog number
88-7966-29; TNF-a catalog number 88-7346-22; IL-17, catalog
number, 88-7478-22; e-Bioscience – Ready-SET-Go) following
the manufacturer’s instructions.The sensitivity of the assay was
2 pg/mL for IL-6 and 4 pg/mL for TNF-a and IL-17.2.4. Statistical analysis
The normal distribution of data was analyzed using the Kol-
mogorov–Smirnov test. The correlation between data for the
healthy controls and SCA patients was assessed using the Mann
Whitney test. To compare the cytokine levels between haplotypes,
we used analysis of variance (ANOVA) followed by Tukey’s multi-
ple comparison test or Kruskal–Wallis test followed by Dunn’s
multiple comparisons. Results have been expressed as mean ±
S.E. of the mean (SEM). All statistical analyses were performed
using GraphPadPrism, version 5.01, and p < 0.05 was considered
statistically signiﬁcant.3. Results
3.1. HBBS gene haplotypes
The haplotype study was conducted for the 62 patients with
HbSS. For the samples studied, b–S haplotypes were identiﬁed by
the following algorithm. The Benin/Benin haplotype was (+) for
30wb– HindII, the Bantu/Bantu haplotype was (+) for cG– HindIII,
and the Bantu/Benin haplotype was (+) for cG – HindIII and 3’wb
– HindII. The Bantu haplotype was the most prevalent (86 chromo-
somes, Bantu; 32 patients, homozygous for Bantu/Bantu; and 22
patients, heterozygous for Bantu/Benin), followed by the Benin
haplotype (38 chromosomes, Benin; 8 patients, homozygous for
Benin/Benin; and 22 patients, heterozygous for Bantu/Benin).
Table 2 shows the number of chromosomes and patients with
the Bantu and Benin haplotypes in the population studied.
Table 1
Restriction enzymes used for detection of the haplotypes of the beta S gene cluster; regions of polymorphic sites; size of the DNA fragments before and after cleavage and
polymorphism pattern for each haplotype.
Enzyme Region DNA fragment size (bp) DNA fragments after cleavage Haplotype
Senegal Benin Bantu Cameroon Arab-Indian
XmnI 50cG 650 450 bp + 200 bp + – – – +
HindIII cG 780 430 bp + 340 bp + 10 bp + – + + +
HindIII cA 760 400 bp + 360 bp – – – + –
HincII wb 701 360 bp + 340 bp + 1 bp + – – – +
HincII 30 590 470 bp + 120 bp + + – + +
HinfI 5’ 380 240 bp + 140 bp + – – + –
bp: base pairs
Table 2
Distribution of haplotypes, chromosomes and genotypes in the population studied
(n = 62).
Haplotype Chromossomes (n) RFLPsa Genotype Patients (n)
Bantu 86  +  Bantu/Bantu 32
Benin 38  +  Benin/Benin 8
 +  +  Bantu/Benin 22
n: Number; RFLP: restriction fragment length polymorphism.
a The six RFLP0s used to deﬁne the haplotype are in the following order: 50cG –
XmnI, cG – HindIII, cA – HindIII, wb – HindII, 30wb – HindII, 50b – HinfI.
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Table 3 shows a comparison of the IL-6, IL-17 and TNF-a levels
of the SCA patients and healthy individuals. As expected, the levels
of IL-6, IL-17 and TNF-a were higher in patients with SCA than in
the controls, while there were no signiﬁcant differences in the con-
centrations of IL-17.
3.3. Serum cytokine levels of the patients and the association between
HBBS gene haplotypes
IL-6 and TNF-a levels were higher in subjects with the Bantu/
Bantu haplotype than in those with the Benin/Benin haplotype.
Although a similar trend was observed for IL-17 levels, the differ-
ence observed was not statistically signiﬁcant. The Bantu/Benin
haplotype had lower levels than the Bantu/Bantu haplotype and
higher levels than the Benin/Benin haplotype for both cytokines,
but the differences were not signiﬁcant. Table 4 and Fig. 1 show
the association between the cytokine levels and the various
haplotypes.
3.4. Cytokine levels according to the length of HU treatment and mean
HU in SCAHU patients
The level of the cytokines was not signiﬁcantly inﬂuenced by
the length of treatment or dose of HU (Table 5). Patients who were
on HU treatment forP20 months did not have signiﬁcantly greater
levels of cytokines than those who were on HU treatment for
<20 months. Further, the mean dose of HU did not signiﬁcantly
inﬂuence the cytokine level. Individuals who received a mean HUTable 3
Cytokines levels of IL-6, TNF-a and IL-17 in SCA patients and control group.
Cytokine SCA (n = 62) Controls (n = 30) P value
IL-6 23.87 ± 5.333 5.623 ± 0.7919 0.003*
TNF-a 24.84 ± 6.036 6.008 ± 1.090 0.0258*
IL-17 4.101 ± 0.2770 3.072 ± 0.1754 0.1831
Data are mean ± S.E.M.
* Statistical signiﬁcance according to Mann–Whitney U-test.doseP20.0 mg/kg did not show higher serum cytokine levels than
those who received <20.0 mg/kg.
4. Discussion
Two interrelated events, sickle vaso-occlusion and hemolytic
anemia, indicate clinical severity of the sickle cell disease [4].
Inﬂammation appears to play a signiﬁcant role in the clinic in
sickle cell disease, and the endothelium plays a critical role in
the propagation and perpetuation of the chronic inﬂammatory
state that characterizes SCA [34]. Endothelial activation and dam-
age can be provoked by adherent sickle cells, inﬂammation, and
circulatory shear stresses. It is believed that signiﬁcant subclinical
microvascular occlusions occur in SCA. These subclinical vaso-
occlusions are induced by the enhanced adhesiveness of reticulo-
cytes and sickled erythrocytes to the vascular endothelium [35],
by the association between chronic endothelial activation and in-
jury, and by the production of proinﬂammatory cytokines by these
activated endothelial cells [2]. The cytokines and chemokinespro-
duced by the activated endothelium contribute to the pan-cellular
activation that results in the high circulating levels of the numer-
ous inﬂammatory molecules encountered in SCA patients, such
as TNF-a, IL-6, and IL-17 [36–39]. These cytokines produced during
inﬂammatory stress are also potent activators of the endothelium,
an effect that creates the vicious circle leading to the perpetuation
of inﬂammatory mediator production, cell adhesion to the vascular
wall, and, eventually, chronic inﬂammation [40].
Our study has demonstrated that SCA patients have an in-
creased inﬂammatory proﬁle compared to healthy individuals.
The concentrations of IL-6 and TNF-a were signiﬁcantly higher in
SCA patients than in the controls. Although the IL-17 concentra-
tions showed an increasing trend in the SCA patients, the levels
were not signiﬁcantly higher than those of the healthy controls.
Recent studies have conﬁrmed these results [38,41,42]. Pathare
et al., [9] studied 60 SCA patients during the steady state (n = 26)
and in painful crisis (n = 34) and compared them with normal
healthy non anemic blood donors (n = 20). They observed that
the mean serum IL-6 and TNF-a levels were higher in SCA patients
than in normal controls but that this increase was not statistically
signiﬁcant.
The beta S-globin gene haplotypes have been shown to corre-
late with the clinical features of SCA patients. A study on Africans
who had SCA, differing b-globin gene cluster haplotypes, and dis-
tinct hematological characteristics suggested that haplotypes
could be a marker for the phenotypic heterogeneity observed in
SCA [24,25].
For example, carriers of the HbS gene for the Senegal or Arab-In-
dian haplotype usually have the mildest clinical symptoms be-
cause they are the only ones with the C–T SNP located at 158 bp,
50 to HBG2 (originally known as the Xmn1 restriction enzyme site).
Previous reports have suggested that the Bantu haplotype is asso-
ciated with a higher incidence of organ damage with more severe
Table 4
Cytokine levels in SCA patients according to HBBS gene haplotypes.
Cytokine Haplotype P value
Bantu/Bantu(n = 32) Bantu/Benin (n = 22) Benin/Benin (n = 8)
IL-6 33.29 ± 10.02 15.81 ± 5.989 8.513 ± 3.870 0.0065*
TNF-a 21.03 ± 8.111 16.14 ± 5.255 11.69 ± 1.230 0.0486*
IL-17 4.507 ± 0.5414 4.134 ± 0.4780 3.005 ± 0.2405 0.9658
Data are mean ± S.E.M
* TNF-a e IL-6 Statistical signiﬁcance according to Kruskal–Wallis test and Dunn’s Multiple Comparison pos-test.
Fig. 1. Plasma levels of TNF-a, IL-6 and IL-17 to each HBBS gene haplotypes in patients SCAHU. ⁄p-Value.
Table 5
Cytokines levels according to length of HU treatment and mean HU in patients with
SCAHU.
TNF IL-6 Il 17
Length of HU treatment
<20 months 24.11 ± 6.891 24.14 ± 8.359 4.068 ± 0.3471
P20 months 21.46 ± 8.047 23.76 ± 7.610 4.357 ± 0.3714
P value 0.2770 0.2418 0.3641
Mean dose of HU
<20 months 23.09 ± 6.148 16.32 ± 16.32 4.058 ± 0.3861
P20 months 22.02 ± 8.702 29.54 ± 9.111 4.387 ± 0.3609
P value 0.2392 0.4823 0.2257
Data are mean ± S.E.M.
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form of SCA [20,21,23].
Other studies have described beta S-globin gene haplotypes and
their inﬂuence on the oxidative stress and DNA damage in SCA pa-
tients, where the Bantu haplotype is associated with poor progno-
sis too [19,43].
With respect to the association between inﬂammatory proﬁle
and haplotypes, this study showed that concentrations of IL-6
and TNF-a for the Bantu/Bantu haplotype were greater than those
for the Benin/Benin haplotype and that the Bantu/Benin haplotype
had lower values than the Bantu/Bantu haplotype and greater val-
ues than the Benin/Benin haplotype. For IL-17, a slight trend to-
ward decrease was observed in the Benin/Benin haplotype when
compared with the Bantu/Bantu and Bantu/Benin haplotypes,
although the differences were not statistically signiﬁcant. Thus,our results show that genetic polymorphisms in SCA are associated
with the inﬂammatory proﬁle.
The results of this study showed that the levels of the proin-
ﬂammatory cytokines for the Bantu/Bantu haplotype were signiﬁ-
cantly greater than those for the Benin/Benin haplotype. This could
be one possible explanation for the fact that the Bantu haplotype is
associated with worse prognosis and with greater variety of clini-
cal manifestations. With the increased inﬂammatory proﬁle, Ban-
tu/Bantu patients are more prone to clinical complications such
as vaso-occlusive pain crises and splenic sequestration. On the
other hand, the Benin haplotype showed lower levels of proinﬂam-
matory markers, which justiﬁes the lower risk of developing clini-
cal complications from the inﬂammatory response and thus of
having a better prognosis.
Many previous studies have investigated prognosis, prevention
of organ damage, and improvement of the quality of life in SCA pa-
tients; the novel aspect of the current study is that its ﬁndings indi-
cate that the inﬂammatory proﬁle can vary according to the
genetic polymorphisms of the patient.
In conclusion, the present study provides two important ﬁnd-
ings: patients with SCA have an increased inﬂammatory proﬁle
and that patients with the Bantu/Bantu haplotype show greater
levels of proinﬂammatory cytokines than those with the Bantu/Be-
nin or Benin/Benin haplotype.
Our results suggest that the inﬂammatory proﬁle in sickle cell
disease seems to be associated with genetic polymorphisms and
therefore further research is required on inﬂammation in and the
genetic characteristics of SCA. Further studies on the genetic proﬁle
of SCA patients may help guide adjuvant treatment decisions.
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